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integrated chronic care approach in patients with atrial fibrillation compared to
usual care. The objective of the present study is to assess cost-effectiveness of this
nurse-led care program versus usual care.METHODS:A cost effectiveness analysis
was undertaken alongside the randomized controlled trial in which 712 patients
were included at the Maastricht University Medical Centre, Maastricht, The Neth-
erlands, and allocated to nurse-led care or usual care. Nurse-led care implied
guideline adherent management, steered by dedicated software and supervised by
cardiologists. Usual care was regular outpatient care performed by cardiologists. A
cost per lifeyear as well as a cost per QALY analysis was performed, both from a
hospital perspective. QALYs were based on scores of the Short Form 36 question-
naire (SF-36), converted to utility scores by extracting the Short Form 6D (SF-6D). All
unit prices were supplied by the hospital’s financial department, except for prices
for medication, which were taken from the Dutch Pharmacotherapeutic Compass.
Results represented the costs and effects for a 12 months follow-up period.
RESULTS: The nurse-led care program was associated with slightly more lifeyears
and QALYs at a lower cost. Specifically, the nurse-led program contributed to 0.086
QALY gains with a reduced cost of € 1102.77 per patient and a gain of 0.02 life years
with a reduced cost of € 731.62 per patient. Therefore, the nurse-led program would
be considered dominant. In fact, for all the possible values of willingness to pay for
a QALY the nurse-led program is considered to be more likely cost effective than
the care as usual. CONCLUSIONS: The cost-effectiveness analysis in the present
study demonstrated that a nurse-led integrated care approach is very likely a cost-
effective management strategy for patients with atrial fibrillation.
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OBJECTIVES: To demonstrate the lowest expected cost of the interventions for the
treatment of insomnia in elderly after considering the various costs and utilities
associated with adverse events; falls in particularly using a decision tree.
METHODS: A decision tree was used to estimate the lowest expected cost and
cost-effectiveness of two interventions with untreated elderly population suffering
from insomnia. The economic analysis estimates the average total cost of treat-
ment with benzodiazepines and cognitive behavioural therapy plus the cost asso-
ciated with adverse events due to benzodiazepines and cognitive behavioral ther-
apy, based on published data sources, and average QALYs lost due to various
adverse events associated with use of benzodiazepines.Incremental cost-utility
ratio (ICUR) was calculated to estimate the additional costs of cognitive behavioural
therapy (over benzodiazepines) associated with the use of cognitive behavioural
therapy to achieve a gain of one additional QALY (over benzodiazepines). RESULTS:
Ranking analysis of different strategies revealed that cognitive behavioural ther-
apy is 33% cheaper with an incremental value of CAD$725.13 compared to un-
treated insomnia and 56% cheaper with an incremental value of $1158.81 com-
pared to benzodiazepines treatments. Cognitive-behavioral therapy was the
clearly in dominance and dominate bezodiazepines with an ICER of -46520 and
untreated insomnia with an ICER of -27251. Monte-carlo probabilistic sensitivity
analysis shows the cognitive behavioral therapy as the optimal strategy with a net
monetary benefit of CAD$30809.40. CONCLUSIONS: This case example using in-
somnia and the risk of falls in the elderly demonstrates that current treatment
reimbursement options that fund pharmacologic but not non-pharmacologic ther-
apy for geriatric insomnia are neither cost-saving nor ethically recommendable
from the health system’s perspective.A major restructuring of decision-making
processes for reimbursement of treatment options for chronic non-life threatening
conditions is required that considers age-related adverse treatment effects
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OBJECTIVES: We conducted a cost-effectiveness analysis (CEA) on two strategies:
routine HIV counseling and testing (RCT) and home-based HCT (HBHCT) in
Kayunga District, Uganda. METHODS: A decision-analytic model was developed to
evaluate the cost-effectiveness of RCT and HBHCT for provision of HCT to the
population between 2008 and 2010. The reference case was a 30-year old woman in
Kayunga District and the provider perspective was adopted. Costs for HCT were
obtained from project records (MUWRP) and the main outcome measure (effective-
ness) was the number of people who got to know their HIV sero-status in the review
period. Data were analyzed using Tree-age Pro 2011®software. RESULTS: Of 68,650
clients who underwent RCT strategy, only 49.7% (34,138) received their HIV test
results. For HBHCT, 45,000 clients were counseled and tested and 70.6% (31,813)
received their HIV test results. The probability of counseling and testing a HIV
positive client was 0.11 for RCT and 0.03 for HBHCT. The unit cost of providing HCT
was $4.39 for RCT and $10.45 for HBHCT. RCT had an incremental cost of $4.60 and
an incremental cost effectiveness ratio of $15.10 per individual offered HCT.
CONCLUSIONS: In this study, RCT was the more cost-effective strategy. However,
HBHCT was more effective in terms of reaching out to more people who get to know
their HIV sero-status. Basing on the findings of this study, RCT should be prioritized
in all health centers while targeting HBHCT for high burden and hard to reach
settings.
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OBJECTIVES: To assess cost-effectiveness of infant vaccination with 10-valent
pneumococcal non-typeable Haemophilus influenzaeprotein-D conjugate vaccine
(PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV13) versus no vacci-
nation in Russia. METHODS: The analysis was performed for a 10-year and a life-
time horizons from health care and societal perspectives. In the analysis only the
direct effect of vaccination was assessed. The effect on invasive pneumococcal
diseases (meningitis, bacteriemia), community acquired pneumonia and pneumo-
coccal acute otitis media (AOM) was evaluated for both vaccines. The effect of
PHiD-CV on AOM caused by non-typeable Haemophilus influenzae was also con-
sidered. Medical costs were estimated based on tariffs of obligatory medical insur-
ance in Saint-Petersburg in 2012. Vaccine cost/dose and schedule of infant vacci-
nation (two doses followed by booster dose) were assumed to be the same for both
vaccines. Indirect costs included illness allowance and productivity losses. Costs
and health benefits were discounted at 3.5%/year. Willingness to pay threshold was
assumed as 1 GDP/capita (approximately 380 KRUB). Sensitivity analysis was con-
ducted on main parameters (incidence data, vaccines effectiveness, costs).
RESULTS: The research showed that incremental cost-effectiveness ratios (ICERs)
for both vaccines are very close. Considering health care perspective ICERs for
PHiD-CV and PCV13 were 376.5 and 383.3 KRUB/1 life year gained (LYG) respectively
at 10-year horizon; 89.1 and 91.1 KRUB/1 LYG at a lifetime horizon. Considering
societal perspective ICERs were 312.6 and 333.3 KRUB/LYG for PHiD-CV and PCV13
respectively at 10-year horizon; both vaccines were shown to be dominating alter-
natives at a lifetime horizon. Sensitivity analysis indicated that results were more
sensitive to incidence data and costs. CONCLUSIONS: Vaccination of infants in
Russia with PHiD-CV and PCV13 is cost-effective at a 10-year horizon. PHiD-CV in
base case analysis had a little bigger potential cost offset compared to PCV13. Both
vaccines could be recommended for inclusion in the Russian national immuniza-
tion calendar.
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OBJECTIVES: Treatment with antiepileptic drugs is commonly guided by serum
level monitoring. Such monitoring requires expensive laboratory equipment and
products. However, well-conducted studies on the cost-effectiveness of therapeu-
tic drug monitoring for antiepileptic drugs are lacking particularly in patients with
structural-metabolic epilepsy. Moreover, there are contradictory thoughts on the
importance of using serum-level monitoring to optimise antiepileptic drugs ther-
apy. The study aims to assess the cost-effectiveness of serum level monitoring
services in the management of children diagnosed with structural-metabolic
epilepsy. METHODS: A retrospective cost-effectiveness analysis was conducted
from the provider perspective. It included patients attended a paediatric neurology
clinic. The effectiveness measures used in this analysis were the number of pa-
tients that achieved 50% reduction in seizure frequency, and the number of pa-
tients with 3-month seizure free. Medical records of the patients were reviewed for
the required information. Medical chart/billing data obtained from the hospital
were collected to estimate the resources used. The recruited children were fol-
lowed for one year following their first visit. RESULTS: The average cost effective-
ness ratio for the monitored patients (MYR 2,735 per patient that achieved a 50%
reduction in seizure frequency) was lower than that for non-monitored patients
(MYR 2,921 per patients that achieved a50% reduction in seizure frequency), with
incremental cost-effectiveness ratio of MYR 2,357 per one additional patient that
achieved a 50% reduction in seizure frequency. The average cost effectiveness
ratios for monitored and non-monitored group were MYR 8,279 and MYR 6,433 per
patient with a 3-month seizure-free period, respectively, with incremental cost-
effectiveness ratio of MYR 29,666 per one additional patient with a 3-month sei-
zure-free period. CONCLUSIONS: In terms of the effectiveness measures used,
serum level monitoring of antiepileptic drugs was found to be cost-effective. How-
ever, the incremental cost-effectiveness ratio was found to be sensitive to the cost
of management.
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OBJECTIVES: Universal hepatitis B vaccination policy has not been introduced in
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